Erasca: Hype Building Into The End Of The Year (Rating Downgrade) (NASDAQ:ERAS)

Core Insights - The year 2025 has seen significant advancements for companies targeting the RAS/MAPK signaling pathway in cancer treatment [1] Company and Industry Summary - Companies are exploring new possibilities in the RAS/MAPK signaling pathway, indicating a growing interest and investment in cancer research and treatment [1]